Sinovac Biotech Ltd. develops, manufactures and commercializes vaccines and related biological products for human infectious diseases. The China-based biopharmaceutical company’s marketed portfolio includes vaccines for influenza, viral hepatitis, varicella, hand-foot-mouth disease associated with EV71, poliomyelitis, pneumococcal disease and COVID-19, and its pipeline includes combination vaccines, recombinant protein vaccines, mRNA technologies and antibodies.
Company updates commonly address vaccine sales, research and development progress, product approvals, overseas market activity and financial reporting. Recent corporate developments also include Nasdaq listing-compliance matters, auditor engagement, SEC filing status and governance proceedings involving board composition and shareholder-meeting disputes.
Sinovac (NASDAQ: SVA) reported unaudited H1 2025 results: sales $130.3M, gross profit $81.5M (margin 62.5%), and net loss attributable to common shareholders $21.7M or $0.30 per share. Cash and restricted cash totaled $4.2B. Overseas sales rose 29.4%. The company recorded a $68.1M impairment on IPR&D and goodwill and declared a special cash dividend of $55.00 per share.
Key R&D milestones include marketing approval for an adsorbed tetanus vaccine and multiple programs entering Phase III or Phase I trials. Prior-period financials were restated and should no longer be relied upon.
Sinovac (Nasdaq: SVA) filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission on April 30, 2026. An electronic copy is available on the company's investor relations website and on the SEC website.
Sinovac (Nasdaq: SVA) said the Nasdaq Hearings Panel granted its request to continue listing, conditional on remediation of filing delinquencies and completion of its financial audit.
The company must demonstrate compliance by May 11, 2026 by filing its Form 20-F for year ended Dec 31, 2024 and an interim Form 6-K containing an end-of-second-quarter 2025 balance sheet and income statement. Sinovac disclosed it engaged Zhonghua Certified Public Accountants LLP as its independent registered public accounting firm (disclosed Jan 4, 2026) and is working with Zhonghua to complete the required audit and regain compliance.
Sinovac (NASDAQ: SVA) said the Antigua High Court updated an interlocutory order naming ten directors to comprise the Company board until the trial listed in late April/early May 2026, and noted that Rui-Ping Xiao resigned for personal reasons. The Company also announced the Audit Committee approved engagement of Zhonghua as independent auditor effective December 31, 2025. Zhonghua is registered in China and with the PCAOB, and its engagement supersedes UHY LLP.
The company said seven of nine board members are independent and all Audit, Compensation and Nominating & Corporate Governance committee members are independent.
Sinovac (NASDAQ: SVA) received a Nasdaq notification dated January 2, 2026 saying the company was not in compliance with Nasdaq Listing Rule 5250(c)(2) after failing to timely file a Form 6-K containing an interim balance sheet and income statement for the second quarter of 2025.
As previously disclosed, Nasdaq issued a delisting determination in November 2025; the company requested a hearing on November 19, 2025. Nasdaq informed Sinovac the Nasdaq Hearings Panel will consider the late‑filing notice at a hearing scheduled for January 8, 2026, where Sinovac has been invited to present its plan and views aimed at maintaining its Nasdaq listing.
Sinovac (NASDAQ: SVA) announced that the Antigua High Court made an interim order appointing eight directors as the Company's Board until the trial of a disputed Special Shareholders Meeting, now listed for late April/early May 2026. The court hearing occurred on 27 October 2025, and the dispute concerns the outcome of the 8 July 2025 Special Shareholders Meeting.
A Board meeting on 17 December 2025 reaffirmed commitment to shareholder value, to complete the audit with the Audit Committee, to work with management and advisors, to seek restoration of NASDAQ trading, and to pursue negotiated resolutions among parties.
Sinovac (Nasdaq: SVA) received a delisting determination from Nasdaq on November 12, 2025 for non-compliance with Nasdaq Listing Rule 5250(c)(1) after failing to timely file its Form 20-F for the year ended December 31, 2024 by the extension deadline of November 11, 2025.
The company previously disclosed Grant Thornton Zhitong's resignation on April 15, 2025, engaged UHY LLP as its new independent registered public accounting firm on October 24, 2025, and intends to request a hearing with the Nasdaq Hearing Panel on or before November 19, 2025 to appeal the Staff Determination and seek stays of any suspension or delisting while UHY completes the audit.
Summary not available.
SINOVAC (NASDAQ: SVA) announced that its Audit Committee approved the engagement of UHY LLP as the company’s independent auditor, effective October 24, 2025. UHY will audit SINOVAC’s financial statements for the years ended Dec 31, 2021–2025, perform internal control audits as of Dec 31, 2024 and 2025, and conduct interim reviews for the six-month periods ended June 30, 2024 and 2025.
The company said it plans to file Form 20-Fs and Form 6-Ks as soon as practicable to meet SEC and NASDAQ compliance requirements, and described the appointment as a critical step toward improved transparency and the aim of resuming trading on NASDAQ Beijing.
SINOVAC Biotech (NASDAQ: SVA) has issued a statement regarding its July 8, 2025 Special Meeting of Shareholders, which was validly adjourned by Chairman Chiang Li due to pending litigation in Antigua concerning disputed PIPE shares. The company is addressing unauthorized actions by SAIF and the Dissenting Investor Group, who allegedly conducted an invalid meeting after the official adjournment.
The current Board, led by Dr. Chiang Li, maintains its authority and continues to execute key priorities, including: dividend distributions, a special cash dividend of $55.00 per share, working towards NASDAQ trading resumption, appointing a new auditor, and exploring a potential Hong Kong Stock Exchange listing.
The Special Meeting will be reconvened once the Antigua court makes a final decision on the validity of the PIPE shares issued to Advantech/Prime and Vivo Capital.